Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Silo enters into commercial evaluation license agreement for next generation liposomes
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Brings 25 years of global operations and supply chain experience to Piramal
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
Subscribe To Our Newsletter & Stay Updated
